Minister says Indian pharma sector can grow to 65 bln USD by 2024
Indian minister for chemicals and fertilizers D. V. Sadananda Gowda Thursday said the country was one of the largest manufacturers and exporters of generic medicines across the world.
"Indian pharma sector can grow to 65 billion U.S. dollars industry by 2024," Gowda said. "We have recently launched schemes for the development of seven mega parks-three bulk drug parks and four medical device parks across the country."
"New manufacturers will be eligible for the Production Linked Incentive (PLI) Scheme under which they will be eligible for financial incentives on basis of their sales for the first five to six years."
During the initial phase, he said, Hydroxychloroquine (HCQ) and Azithromycin was identified as one of medicines under treatment protocol for COVID-19 in emergency cases.
The minister said India earned the reputation of reliable suppliers of medicines as it supplied these medicines to more than 120 countries across the world.
Addressing a video conference FICCI LEADS 2020, the minister highlighted that India is one of the largest manufacturers and exporter of generic medicines across the world.
Gowda also said the market size of chemicals and petrochemicals sector in India is around 165 billion U.S. dollars, and the size was expected to grow up to 300 billion U.S. dollars by 2025.
2026-09-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
Urea Prices Surge as India Faces Critical Shortages: Will China’s Export Quotas Provide Relief?
-
MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?
-
“Deregulation” or “Concession”? The Hidden Crisis Behind India’s Repeal of QCOs on Seven Key Petrochemicals
-
Do You Know the Food Zero Additives?
-
China’s Titanium Dioxide Giant Makes a Move: LB Group Acquires UK Venator Assets
-
The Game Between Supply and Demand Tends Toward Equilibrium; Formic Acid Ranges Sideways
-
This Round of Refined Oil Retail Prices Achieves "Six Consecutive Increases" in China
-
High-level Plateau Interval Stabilization: Review and Future Trend Prediction of the Melamine Market in China in April
-
Supply Contraction Meets Weak Consumption—PCs Consolidate in Early May
-
Premium Global Chemical Sourcing Requests (07-10May, 2026)